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S U M M A R Y
Background: Since the ﬁrst description of Middle East respiratory syndrome coronavirus (MERS-CoV), it
has not been known how long patients shed the virus in respiratory secretions. Thus, we analyzed the
available data on time to negative MERS-CoV test in patients with conﬁrmed MERS-CoV infection and
asymptomatic positive contacts.
Methods: Data from repeated laboratory testing of respiratory samples received at the Saudi Arabian
virology reference laboratory in Jeddah, Kingdom of Saudi Arabia from September 1, 2012 to September
31, 2013 were recorded. A real-time RT-PCR test for MERS-CoV was used. Data were analyzed by origin of
sample, sample type, and MERS-CoV PCR test results.
Results: Twenty-six individuals (13 patients and 13 contacts) had repeated testing done until a negative
test was obtained. Most samples from MERS-CoV cases were tracheal aspirate/sputum (p = 0.0006) and
most samples from contacts were nose and throat swabs (p = 0.0002). Kaplan–Meier curve analysis
showed that contacts cleared the virus at a much earlier time than patients. On day 12, 30% of contacts
and 76% of cases were still positive for MERS-CoV by PCR.
Conclusions: Contacts cleared MERS-CoV earlier than ill patients. This ﬁnding could be related to the
types of sample as well as the types of patient studied. More ill patients with signiﬁcant comorbidities
shed the virus for a signiﬁcantly longer time. The results of this study could have critical implications for
infection control guidance and its application in healthcare facilities handling positive cases.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Since the emergence of Middle East respiratory syndrome
coronavirus (MERS-CoV) in 2012, there have been 755 cases with a
total 320 deaths in the Kingdom of Saudi Arabia.1 The virus was
initially thought to affect older adults and those with underlying
medical conditions.2 The reporting of asymptomatic and mildly
symptomatic cases decreased the overall mortality rate and the
mean age.3 Data on viral kinetics in the respiratory tract and other
body ﬂuids are scarce. In a recent case study, MERS-CoV shedding
from the respiratory tract was detected until day 24 of illness.4 In
this study we investigated the viral shedding of MERS-CoV in the* Corresponding author.
E-mail address: zmemish@yahoo.com (Z.A. Memish).
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).respiratory secretions of patients who were ill and those with mild
disease who underwent repeated testing.
2. Methods
Patients who underwent more than one virological test for
MERS-CoV at least 1 day apart were included in the analysis.
Repeat testing was done non-systematically using respiratory tract
samples from September 1, 2012 to September 31, 2013.
The types of respiratory specimen collected from patients and
contacts were sputum samples, nose and throat swabs, nasopha-
ryngeal swabs, and endotracheal aspirate samples.
With regard to MERS-CoV screening, clinical samples were
screened by real-time PCR (RT-PCR) ampliﬁcation test, as
described previously, with ampliﬁcation targeting both the
upstream E protein gene (upE) and ORF1a for conﬁrmation; these
are standard assays used in KSA for MERS-CoV testing.2,5ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Sample types based on the category of the patient (cases vs. contacts)
Nasopharyngeal,
n (%)
Nasal and
throat, n (%)
Tracheal aspirate/
sputum, n (%)
Cases (n = 26) 8 (30.7) 2 (7.8) 16 (61.5)
Contacts (n = 20) 6 (30) 12 (60) 2 (10)
p-Value 1.0 0.0002 0.0006
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Figure 1. Kaplan–Meier curve showing time to negative test for cases and contacts.
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negative repeat MERS-CoV RT-PCR test. ‘Positive test’ curves were
drawn for patients and contacts who had repeated testing. The
statistical signiﬁcance of the difference between the curves was
assessed using a log-rank test. SPSS software (SPSS for Windows,
Version 11. Chicago, IL: SPSS Inc.; 2002) was used for the analysis.
3. Results
Twenty-six individuals (13 patients and 13 contacts) under-
went repeat respiratory sample testing until a negative test result
was obtained. Table 1 shows the specimen type by category. Most
samples from MERS-CoV cases were tracheal aspirate/sputum
(p = 0.0006) and most samples from contacts were nose and throat
swabs (p = 0.0002). The Kaplan–Meier curve showed that contacts
cleared the virus at a much earlier time than patients (Figure 1). On
day 12, 30% of contacts and 76% of cases were still positive for
MERS-CoV by PCR.
4. Discussion
The viral kinetics and the time of shedding of MERS-CoV in the
respiratory tract are not known. In previous case reports, MERS-CoV
was isolated from the respiratory tract secretions up to day 24 in one
patient,4 and day 18 in another.6 In this large retrospective analysis,
cases had more prolonged viral shedding from the respiratory tract
than contacts. The difference is related to the severity of the disease
and the signiﬁcant underlying comorbidities among the cases.
However, the study did not examine viral shedding systematically
and thus patients with more severe disease may have been selected
for repeat testing rather than those who had milder disease. A
systematic and prospective study is required to further delineate the
kinetics of MERS-CoV, not only in respiratory secretions but also in
other body ﬂuids (blood, urine, and stool). The reporting of these
data is important to further characterize the pathogenesis of this
disease and for better application of the infection prevention andcontrol measures required. The need to quantify the viral load is also
very important for any recommendations regarding the need for
isolation of those who continue to have positive MERS-CoV by PCR.
The presence of viral RNA in respiratory secretions may indicate a
replicating or a dead virus.
Although the data showed a difference between cases and
contacts – contacts had more upper respiratory tract swabs tested,
while cases had lower respiratory tract samples tested – the
difference could be attributed to the sample type rather than the
exposure type. We have previously shown that lower respiratory
tract samples yield higher MERS-CoV viral loads and genome
fractions than upper respiratory tract samples.7 Since cases had
lower respiratory tract samples collected more often than upper
respiratory tract samples, this indicates that cases were more ill
and probably shed virus much longer. This ﬁnding, if conﬁrmed by
the prospective systematic collection of respiratory samples,
would highlight the importance of applying prolonged infection
control measures in severely ill patients with MERS-CoV in the
healthcare setting. The pattern of transmission of MERS-CoV is
well characterized as sporadic, intra-familial, and healthcare-
associated.8–10 The transmission of MERS-CoV within healthcare
facilities was noted in the Al-Hasa outbreak,11 and of 95 cases in
one report, 63.2% were healthcare-associated and 13.7% were
intra-familial transmission.12 In support of the low infectivity of
asymptomatic and mildly symptomatic cases is the ﬁnding of a low
transmission rate within family contacts.13
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